✦ LIBER ✦

CYP1A1 activity in renal cell carcinoma and in adjacent normal renal tissue

✍ Scribed by Rintala, Sirpa ;Tammela, Teuvo L. J. ;Tuimala, Risto

Publisher: Springer
Year: 1998
Tongue: English
Weight: 229 KB
Volume: 26
Category: Article
ISSN: 0300-5623
DOI: 10.1007/s002400050033

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Glutathione transferase activities in re

Glutathione transferase activities in renal carcinomas and adjacent normal renal tissues: factors influencing renal carcinogenesis induced by xenobiotics

✍ Evert H. Delbanco; Hermann M. Bolt; Wolfgang W. Huber; Sonja Beken; Frank Geller 📂 Article 📅 2001 🏛 Springer-Verlag 🌐 English ⚖ 249 KB

Measurement of progesterone receptor in

Measurement of progesterone receptor in human renal cell carcinoma and normal renal tissue

✍ Michael W. McDonald; Ananias C. Diokno; Dr. Jan C. Seski; K. M. J. Menon 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 258 KB

## Abstract Progesterone receptor was measured in eight samples of renal cell carcinoma, nine samples of normal renal tissue, and one sample of melanoma tissue. Progesterone receptor was identified in all samples, with the exception of one renal cell carcinoma. Three patients, all with receptor‐pos

Telomerase activity in renal cell carcin

Telomerase activity in renal cell carcinoma

✍ Ken-ichiro Yoshida; Shu-ichi Sakamoto; Shuhei Sumi; Yotsuo Higashi; Satoshi Kita 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views

## BACKGROUND. Telomerase activity has been shown to be increased in numerous tumors and cell lines, although to the authors' knowledge there has been no previous assessment of telomerase activity in renal cell carcinoma (RCC). To examine whether telomerase activity could be used as a biochemical p

PTEN/MMAC1/TEP1 mutations in human prima

PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines

✍ Kei-ichi Kondo; Masahiro Yao; Kazuki Kobayashi; Shinsuke Ota; Minoru Yoshida; Sh 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 188 KB 👁 2 views

Tumor-associated trypsin inhibitor in no

Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients

✍ Annukka Lukkonen; Susanna Lintula; Kristina von Boguslawski; Olli Carpén; Börje 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 415 KB 👁 2 views

Tumor-associated trypsin inhibitor (TATI) is a 6-kDa peptide, which is identical to the pancreatic-secretory-trypsin inhibitor (PSTI). TATI is produced by several tumors and cancer cell lines, and is used as a serum marker for mucinous ovarian cancer. Elevated serum levels of TATI have also been obs

TYPE-1 PLASMINOGEN ACTIVATOR INHIBITOR I

TYPE-1 PLASMINOGEN ACTIVATOR INHIBITOR IN HUMAN RENAL CELL CARCINOMA

✍ WAGNER, STEPHAN N.; ATKINSON, MICHAEL J.; THANNER, STEPHANIE; SCHMITT, MANFRED; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 597 KB

In experimental models, plasminogen activator-mediated degradation of the extracellular matrix is inhibited by type-1 plasminogen activator inhibitor (PAI-1). PA14 has also been shown to protect tumour stromal tissue from autoproteolytic activities and may thus substantially promote tumour growth an